Group items tagged

Robert Maltbie of Singular Research talks more about his firm's outlook and top picks for 2012. Find out why he thinks it's a stock picker's market.

Robert Maltbie of Singular Research shares his firm's best idea for the week. This medical equipment maker's diversified product portfolio has some legs for growth.

Robert Maltbie of Singular Research shares his frim's best idea for the week. This precision technology company is working on pinpointing growth.

Robert Maltbie of Singular Research shares his firm's best idea for the week. This EMS provider is breaking the mold of a traditionally low-margin industry.

Robert Maltbie of Singular Research highlights the firm's best idea of the week. The focus here is on a value play that could be poised for a rebound.

Robert Maltbie of Singular Research shares five names that may have struggled through 2011, but come January could be ready to recover in 2012.

Robert Maltbie of Singular Research tells us why this SaaS company is beating the bears with a consistent growth strategy and has strong long-term potential.

Robert Maltbie of Singular Research shares his firm's best call of the week. Despite lowered projections, this company's book-to-bill ratio could be a sign of solid growth.

Robert Maltbie of Singular Research shares his firm's best idea of the week. This innovative biotech company has a proven product and is about to ramp up market share growth.

Robert Maltbie of Singular Research discusses this week's best call: a household name that pioneered and evolved various media strategies to market and sell products directly to consumers.

Investors are once again climbing a wall of worry. Robert Maltbie of Singular Research talks about what he thinks are the biggest risks ahead and the impact of the Facebook IPO.

The most recent published by Reports & Insights termed as "Compounding Chemotherapy Market: Opportunity Analysis and Future Assessment 2022-2030" provides exclusive information about the market, covering in-depth data about future market opportunities and prospects along with the possible challenges. It further mentions recent trends and impact of various factors which affects the growth of XYZ market. Moreover, the report also thoroughly states about the leading players competing in the market for the interest of its readers. The compounding chemotherapy market is estimated to reach at a value of US$ 501.5 Mn by the end of 2022 and expected to reach at a value of US$ 869.5 Mn by 2030 with a significant CAGR of 7.1%. Request a Sample Copy of this Report @: https://reportsandinsights.com/sample-request/2684 Compounding Chemotherapy Introduction Compounding can be perceived as the branch of knowledge of amalgamating and making medications and drugs that are specific and unexceptional to the necessities of the patients. These anticancer drugs are developed based on the counsel of the healthcare professional in which the singular elements are combined in conformity with the prescribed dose. The qualified and skilled healthcare workers are allowed to update the prescription for the patient fulfilling their particular needs, including dosage formulations, flavors, deficiency of constituents, and strengths for which the patient is allergic or susceptible. Compounding Chemotherapy Market Dynamics The rapid enormous evolution in the healthcare industry in the past couple of decades along with various technological advancements is majorly promoting the idea of compounding chemotherapy in the healthcare sector all around the world, which is ultimately expected to offer major breakthroughs to the growth of the global compounding chemotherapy market in the future years. By the same token, many pioneering and cutting-edge approaches and strategies have authorize

Singular Research's Robert Maltbie discusses this week's best idea for the market. While this company could be facing some headwinds in 2012, its lean structure makes it an interesting play.

Singular Research's Robert Maltbie shares this week's best idea to play consumer spending. Here's one smart way to play penny-pinching shoppers in a tough economy.

Despite the gloom from Europe, U.S. market indicators are actually suggesting bullish trends. Singular Research's Robert Maltbie believes the Santa Claus rally will be coming to town.

Singular Research's Robert Maltbie outlines the best call of the week: a staffing/IT consulting company that has solid growth prospects in multiple verticals.

Singular Research's Robert Maltbie discusses the current market environment and why so many investors are still on the sidelines while sentiment is so bullish.

Robert Maltbie of Singular Research identifies 10 stocks that the smart money have been watching. Find out why Wall Street likes these companies.

Robert Maltbie of Singular Research talks about the underlying strength in the current market and whether investors are shifting to more aggressive strategies on the recovery.